Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study

References

• Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review. Dig Liver Dis. 2021;53(7):803–808. doi:10.1016/j.dld.2021.03.002.
   PubMedGoogle Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/ajg.0000000000000152.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:10.1093/ecco-jcc/jjx009.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14(5):694–709. doi:10.1093/ecco-jcc/jjz195.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287. doi:10.1111/j.1600-065X.2008.00754.x.
   PubMed Web of Science ®Google Scholar
• Fernández-Clotet A, Castro-Poceiro J, Panés J. Jak inhibition: the most promising agents in the IBD pipeline? Curr Pharm Des. 2019;25(1):32–40. doi:10.2174/1381612825666190405141410.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624. doi:10.1056/NEJMoa1112168.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2019;17(8):1541–1550. doi:10.1016/j.cgh.2018.11.035.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736. doi:10.1056/NEJMoa1606910.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. doi:10.1056/NEJM198712243172603.
   PubMed Web of Science ®Google Scholar
• Cohen NA, Steinberg JM, Silfen A, et al. Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes. Dig Dis Sci. 2023;68(4):1464–1472. doi:10.1007/s10620-022-07716-0.
   PubMed Web of Science ®Google Scholar
• Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385–1393. doi:10.1093/ecco-jcc/jjaa075.
   PubMed Web of Science ®Google Scholar
• Ma C, Panaccione R, Xiao Y, et al. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-Severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study. Am J Gastroenterol. 2023;118(5):861–871. doi:10.14309/ajg.0000000000002129.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(1):35–42. doi:10.1093/ecco-jcc/jjaa145.
   PubMed Web of Science ®Google Scholar
• Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective dutch initiative on crohn and colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880–888. doi:10.1111/apt.15689.
   PubMed Web of Science ®Google Scholar
• Shin SH, Oh K, Hong SN, et al. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. Therap Adv Gastroenterol. 2023;16:17562848231154103. doi:10.1177/17562848231154103.
   Web of Science ®Google Scholar
• Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28(1):32–40. doi:10.1093/ibd/izab011.
   PubMed Web of Science ®Google Scholar
• Lucaciu LA, Constantine-Cooke N, Plevris N, et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004. doi:10.1177/17562848211064004.
   Web of Science ®Google Scholar
• Straatmijer T, van Gennep S, Duijvestein M, et al. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol. 2021;33(10):1288–1297. doi:10.1097/MEG.0000000000002028.
   PubMed Web of Science ®Google Scholar
• Straatmijer T, van Schaik FDM, Bodelier AGL, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC registry. Aliment Pharmacol Ther. 2023;57(1):117–126. doi:10.1111/apt.17248.
   PubMed Web of Science ®Google Scholar
• Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15(10):1557–1564.e1. doi:10.1016/j.cgh.2017.02.016.
   PubMed Web of Science ®Google Scholar
• Gupta A, Yu A, Peyrin-Biroulet L, et al. Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(9):1800–1813.e4. doi:10.1016/j.cgh.2020.09.046.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Cingolani L, et al. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study. Expert Opin Pharmacother. 2023;24(14):1649–1656. doi:10.1080/14656566.2023.2230126.
   PubMed Web of Science ®Google Scholar
• Kochar BD, Cheng D, Cai T, et al. Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases. Dig Dis Sci. 2022;67(11):5206–5212. doi:10.1007/s10620-022-07404-z.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance. Ann Rheum Dis. 2023;82(7):901–910. doi:10.1136/ard-2022-223715.
   PubMed Web of Science ®Google Scholar